Gregory Gerken
About Gregory Gerken
Gregory Gerken is a Senior CMC Project Manager at Bristol Myers Squibb in New Brunswick, New Jersey, with extensive experience in pharmaceutical and biotechnology procurement and project management.
Title
Gregory Gerken holds the title of Senior CMC Project Manager at Bristol Myers Squibb. He plays a significant role in the execution and oversight of CMC (Chemistry, Manufacturing, and Controls) projects within the organization.
Company
Gregory Gerken is currently employed at Bristol Myers Squibb, a renowned pharmaceutical company located in New Brunswick, New Jersey, United States. Bristol Myers Squibb focuses on the development and manufacturing of innovative medicines for serious diseases.
Career Background
Gregory Gerken has an extensive career history with Bristol Myers Squibb, having worked in multiple roles including Senior CMC Project Manager, Rotational CMC Project Manager, Senior Category Manager, and Category Manager for Analytical Testing & Device Development Services. His earlier roles included Associate Manager in Biologics Procurement and a Co-op position focused on product strategy and operations planning. Prior to Bristol Myers Squibb, he worked at Genzyme and Rutgers University in various capacities.
Education and Expertise
Gregory Gerken earned both his Master of Science (MS) in Industrial and Systems Engineering and his Bachelor of Science (B.S.) in Bioengineering and Biomedical Engineering from Rutgers, The State University of New Jersey-New Brunswick. His academic background is complemented by his practical expertise in strategic sourcing, procurement project management, and supply chain management within the pharmaceutical and biotechnology industries.
Professional Experience in Pharmaceutical Industry
In his professional journey, Gregory Gerken has managed the strategic sourcing of bio-process raw materials and chemicals, aimed at enhancing the efficiency of pharmaceutical manufacturing operations. He has considerable experience in supplier relationship management, particularly with contract research organizations (CROs) and drug delivery device suppliers. He has also contributed to the development and management of drug delivery devices during his tenure at Bristol Myers Squibb.